Welcome to Tigermed
We are committed to supporting our clients in their clinical development in the best possible way. As the leading clinical Contract Research Organization (CRO) in China, we are dedicated to provide services for new drug research and development and other supporting services to global and Chinese pharmaceutical and biotechnology companies. Since our inception in 2004, Tigermed has always embraced new technologies and partnerships to accelerate product development and generate the clinical evidence that our clients require to demonstrate real-world value.
We are committed to improving health by accelerating the development of innovative and effective treatments for patients everywhere. We aim to excel in clinical trials for the benefit of our clients and patients worldwide by providing our services with fundamental principles like quality, innovation, integrity, and ethical conduct at the core of everything we do.
We constantly support our clients in advancing human health by delivering science-based value and real outcomes. Our aim is to solidify our market leadership and foster a flourishing ecosystem that contributes to the sustainable and long-term growth of the healthcare industry.
A Company Built on Values
To be consistent and uncompromising in our moral and ethical principles in clinical development.
To promote collaboration among cultures and sharing our knowledge and values with others unconditionally.
To respect authorities, clients, colleagues, and all those we collaborate with to deliver high-quality results that matter.
To provide our clients with any information required science-based decision making, honor our commitments, and take ownership of our work.
Learn More about Our History
Since our inception in 2004, Tigermed has been developeing and expanding steadily. We have been adding expertise to our porfolio, experienced colleagues to our teams and subsidiairies to the Tigermed group ever since.
Tigermed was established in Hangzhou on December 15, 2004, and successively set up affiliates in Shanghai, Beijing, Chongqing, and Guangzhou, to complete the framework of functional organization structure.
The Xi’an office opened and the number of employees quickly increased to over 40 colleagues.
The Chengdu and Nanjing offices were set up, and the subsidiary of Shanghai Tigermed Consulting Co., Ltd. was founded.
The Changsha, Shenyang, and Wuhan offices opened.
The Jinan, Tianjin, Harbin, Fuzhou offices opened, and Tigermed had increased the establishment of HunanTiger-Xiangya Drug R&D Co., Ltd.
The offices in Zhengzhou, Changchun, Wenzhou, Kunming, Qingdao were set up in China and the first US-based affiliate opened to enter this market. Meanwhile, Tigermed succeeded in the acquisition of MacroStat (China) Clinical Research Co., Ltd. And during this year, the staff count rose to over 200.
The Nanning and Suzhou offices were set up, Jiaxing Tigermed Data Management Co., Ltd. was established, and the overall number of employees rose to over 400.
This year, 16 offices were set up including offices in Shenzhen, Xiamen, Dalian, Wuxi, Shijiazhuang and the subsidiaries Hangzhou Simo Co., Ltd., Tigermed Research Institute, and Hongkong Tigermed Co., Ltd were set up in the same year.
Tigermed was listed in Shenzhen ChiNex with stock symbol 300347. New offices opened in Hefei, Ningbo, and Taiwan. Additionally, the subsidiaries of Shanghai Tigermed Medical Consulting Co., Ltd. and Fantastic Bio-imaging Co., Ltd. were set up.
The offices in the US, Canada, Australia, Korea, Japan, Malaysia and Singapore were established
Tigermed succeeded in the acquisition of Frontage Laboratories Inc., acquired Beijing Canny Consulting Inc. and Shanghai Suntone International Logistics Co., Ltd. Moreover, the Tigermed Smart Medicine Institute and Jiaxing Clinflash Computer Technology Co., Ltd. were set up.
Tigermed succeeded in the acquisition of South Korea’s largest CRO company DreamCIS Inc. In China, the establishment of Hangzhou Wang Ji Health Technology Co. Ltd., Hangzhou Tai Ji Pharmaceutical Technology Co. Ltd., the acquisition of BMD Co., Ltd.
New offices opened in Zhaoqing, Jiangmen, Huaian, Taizhou, Yancheng, Zhanjiang, and Teddy Clinical Research Laboratory (Shanghai) Co., Ltd. was established.
New offices opened in Binzhou, Liaocheng, and Weihai. Tigermed succeeded in the acquisition of Taizhou Jyton-Kannel Medical Tech.Co. Ltd., and Tigermed Swiss AG. was established.
New offices opened in Jilin, Jiaxing, Taizhou, and Weifang. Tigermed succeeded in the acquisition of Opera Contract Research Organization SRL.
Jointly established Tigerise in Japan with Accerise. Frontage listed on main board of the Stock Exchange of Hong Kong.
Become a Part of Our History
Thanks to our continuous growth, we are always on the lookout for new colleagues and partners to sustain our ambitions. If you would like to learn more about the oppertunities at Tigermed contact us today.
As of Q1 2020, Tigermed had a global presence with 115 offices, laboratories, facilities in China and 10 overseas countries in the Asia-Pacific region, North America and Europe.
This set-up enables Tigermed to provide our clients with support in both local expertise in China and global clinical development programs.
Click locations on the map to see office address.
10F 130 Sajik Ro
Jongno-gu, Seoul 03170
#11-30 Vision Exchange
39C, Jalan SS21/60 Damansara Utama
47400 Petaling Jaya
Selangor Darul Ehsan
Tigermed Japan (Osaka)
9F, 1-5-17 Dojima
Tigermed Japan (Tokyo)
2F, 1-11 Kanda-Ogawamachi
Tigermed China (Taiwan)
1st floor 5/f no. 410 section 5 zhongxiao east road
135 North Square
Tigermed China (Hong Kong)
Level 10, Central Building
1-3 Pedder Street
Central, Hong Kong
Tigermed China (Hangzhou)
Fl.15, Dongguan Plaza
No. 618 Jiangnan Avenue
310053 Hangzhou, China
15/18 Ridge Street
North Sydney NSW 2060
Strada Cozia 10
#106-2738 158th Street,
Surrey BC V3S 3K3
5201 Madison Creek Dr.
Fort Collins, CO 80528
100 Franklin Square Drive Suite 305
Somerset, NJ 08873
700 Pennsylvania Drive
Exton, PA 19341